Heat Biologics, Inc. (NASDAQ:HTBX) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03, Bloomberg Earnings reports. Heat Biologics had a negative return on equity of 148.01% and a negative net margin of 1,479.67%.

Heat Biologics (NASDAQ HTBX) opened at $0.59 on Tuesday. Heat Biologics has a 12-month low of $0.46 and a 12-month high of $3.35.

Separately, Griffin Securities started coverage on Heat Biologics in a report on Tuesday, September 12th. They set a “buy” rating and a $2.25 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $2.13.

COPYRIGHT VIOLATION NOTICE: “Heat Biologics, Inc. (HTBX) Issues Quarterly Earnings Results” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/14/heat-biologics-inc-htbx-issues-quarterly-earnings-results.html.

A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. grew its stake in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 661,388 shares of the biopharmaceutical company’s stock after buying an additional 70,290 shares during the period. Vanguard Group Inc. owned 1.86% of Heat Biologics worth $403,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.64% of the company’s stock.

About Heat Biologics

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Earnings History for Heat Biologics (NASDAQ:HTBX)

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.